NeOnc Technologies Holdings (Nasdaq: NTHI) Announces Investor Call for Phase 1 NEO212-01 Results
NeOnc Technologies Holdings (Nasdaq: NTHI) to Present Key Phase 1 Clinical Trial Data for CNS Cancer Therapy
Conference Call to Reveal Dose-Escalation Results for NEO212-01 Clinical Trial
CALABASAS, Calif., February 27, 2026 — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company focused on therapies for central nervous system (CNS) cancers, has announced a significant upcoming investor conference call and webcast. The call, scheduled for March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET, will unveil dose-escalation results from the full Phase 1 readout of the NEO212-01 clinical trial.
Key Points for Investors
- Presentation of Initial Phase 1 Results: NeOnc will present first data from the dose-escalation portion of its NEO212-01 Phase 1/2 trial, evaluating the company’s proprietary bioconjugated temozolomide (TMZ) platform for CNS malignancies. This includes safety and toxicity data, dose-escalation observations, pharmacokinetics, and regulatory next steps.
- High-Profile Participants: The webcast will feature leading neuro-oncology experts, including Dr. Henry S. Friedman (Duke University) and Dr. Alexandra Miller (NYU Langone Health), both independent members of NeOnc’s Scientific Advisory Board, along with NeOnc’s management team.
- Potential Share Price Catalysts: The release of Phase 1 safety, toxicity, and dosing data is a critical milestone in drug development. Positive results could significantly de-risk the NEO212 program, enhance investor confidence, and potentially move the share price, especially given the program’s advancement under FDA Fast-Track and IND status.
- Advancement of Pipeline: Both NEO100™ and NEO212™ are in Phase II trials, and the company holds patent protections through 2038. The NEO212 program leverages an oral TMZ formulation designed to overcome the blood-brain barrier, a major challenge in CNS cancer therapy.
- Strong Intellectual Property Position: NeOnc holds exclusive worldwide licenses from the University of Southern California for a portfolio of issued and pending patents related to its core technologies, protecting both oncological and neurological uses.
Details of the Investor Conference Call
- Date: March 4, 2026
- Time: 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time
- Webcast Link: https://www.webcaster5.com/Webcast/Page/3151/53708 or visit https://investors.neonc.com
- Featured Speakers:
- Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University
- Dr. Alexandra Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health
- Amir Heshmatpour – CEO, Executive Chairman and President, NeOnc
- Dr. Thomas C. Chen, MD, PhD – CMO and CSO, NeOnc
- Dr. Josh Neman, PhD – Chief Clinical Officer, NeOnc
- Keithly Garnett – CFO, NeOnc
About NeOnc Technologies Holdings, Inc.
NeOnc is a clinical-stage life sciences company developing and commercializing therapies that address the unique challenges of treating CNS diseases, particularly by overcoming the blood-brain barrier. The company’s NEO™ drug development platform has yielded a portfolio of proprietary chemotherapy agents and delivery methods, with extensive patent protection through 2038. These agents have shown efficacy in laboratory and early-stage clinical trials treating various cancers and malignant gliomas. Both NEO100™ and NEO212™ are in Phase II trials and benefit from FDA Fast-Track and IND status.
The company’s broad patent portfolio, exclusively licensed from the University of Southern California, covers key assets and indications in oncology and neurology.
Shareholder Relevance and Price Sensitivity
- This event is highly significant for shareholders: The release of initial Phase 1 safety and dosing data is a major inflection point for NeOnc’s lead asset, NEO212. Positive results could drive increased investor interest, strategic partnerships, and potential upward movement in the company’s stock price.
- Regulatory Progress: Updates on FDA Fast-Track and IND status could impact valuation and future funding opportunities.
- Intellectual Property: Strong patent protection enhances the company’s competitive position and potential for long-term revenue streams.
Contact Information
Disclaimer
Disclaimer: This article contains forward-looking statements regarding NeOnc Technologies Holdings, its clinical programs, and upcoming investor events. Actual results may differ materially from those anticipated due to risks and uncertainties inherent in clinical development, regulatory processes, and market conditions. Investors are advised to conduct their own due diligence and consult with financial advisors before making investment decisions. This article does not constitute investment advice or an offer to buy or sell any securities.
View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here
